ReviewCurrent atherosclerosis reports2020
Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?
Review in Current atherosclerosis reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- The Association of Lipoprotein(a) with Major Adverse Cardiovascular Events after Acute Myocardial Infarction: A Meta-Analysis of Cohort Studies.Reviews in cardiovascular medicine · 2025Pooled it
- The association of triglyceride-glucose index with major adverse cardiovascular and cerebrovascular events after acute myocardial infarction: a meta-analysis of cohort studies.Nutrition & diabetes · 2024Pooled it
- Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies.Cardiovascular diabetology · 2021Pooled it
- Association between depressive symptoms and atherosclerotic cardiovascular disease: a Swedish population-based cohort study.BMC cardiovascular disorders · 2026Article
- Burden of premature atherosclerotic cardiovascular disease and its risk factors among young and middle-aged adults in primary care clinics of Karachi, Pakistan.Journal of health, population, and nutrition · 2026Article
- Advanced machine learning techniques for coronary artery disease risk prediction in early middle-aged adults.BMC medical genomics · 2025Article
- Prevalence of physical activity and its association with atherosclerotic cardiovascular risk factors in young women in the middle east: a sub-analysis of the ANCHORS study.BMC public health · 2025Observational
- Diabetes and risk of premature atherosclerotic cardiovascular disease.Nutrition, metabolism, and cardiovascular diseases : NMCD · 2025Observational
- Sex-specific associations of cigarettes and e-cigarettes use with self-reported premature atherosclerotic cardiovascular disease among adults aged 18-54 in the United States.Preventive medicine · 2025Article
- Comparative analysis of atherosclerotic cardiovascular disease burden between ages 20-54 and over 55 years: insights from the Global Burden of Disease Study 2019.BMC medicine · 2024Article
- Oral Nanoformulations in Cardiovascular Medicine: Advances in Atherosclerosis Treatment.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Association between lipoprotein(a) and premature atherosclerotic cardiovascular disease: a systematic review and meta-analysis.European heart journal open · 2024Article
- Risk factors for atherosclerotic cardiovascular disease (ASCVD) in healthcare professionals of Azar Cohort Study: A cross-sectional Study.Health promotion perspectives · 2024Article
- Associations Between Estimated Pulse Wave Velocity and Five-Year All-Cause Mortality in Patients with Atherosclerotic Cardiovascular Disease with and without Standard Modifiable Risk Factors: Evidence From NHANES 1999-2016.Clinical epidemiology · 2024Article
- Article
- Temporal Trends in Incidence of Premature Cardiovascular Disease Over the Past 7 Decades: The Framingham Heart Study.Journal of the American Heart Association · 2022Article
- Nitrotyrosine, Nitrated Lipoproteins, and Cardiovascular Dysfunction in Patients with Type 2 Diabetes: What Do We Know and What Remains to Be Explained?Antioxidants (Basel, Switzerland) · 2022Review
- Triglyceride-glucose index and estimated 10-year risk of a first hard cardiovascular event.Frontiers in cardiovascular medicine · 2022Article
- Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study.Journal of lipid and atherosclerosis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn contrast to patients with non-premature atherosclerotic cardiovascular disease (ASCVD), patients with premature ASCVD have not observed a similar decline in cardiovascular mortality and recurrent adverse events. We sought to review the underlying risk factors, potential gaps in medical management, associated outcomes, and tools for risk prognostication among patients with premature ASCVD. RECENT
findingsIn addition to traditional cardiovascular risk factors (i.e., diabetes, familial hypercholesterolemia), non-traditional risk factors such as chronic inflammatory conditions, recreational drug use, genetics, and pregnancy-related complications play a key role in development and progression of premature ASCVD. Patients with premature ASCVD, and especially women, receive less optimal medical management as compared to their non-premature counterparts. There is an increasing prevalence of cardiovascular risk factors among young adults. Hence, this population remains at an elevated risk for premature ASCVD and subsequent adverse cardiovascular events. Future studies evaluating different risk assessment tools and focusing on young patients across all three major domains of ASCVD are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.